Harrow (NASDAQ:HROW) and PreveCeutical Medical (OTCMKTS:PRVCF) Head to Head Analysis

Harrow (NASDAQ:HROW) and PreveCeutical Medical (OTCMKTS:PRVCF) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, profitability, earnings, analyst recommendations and risk.

Volatility and Risk

Harrow has a beta of 0.4, indicating that its stock price is 60% less volatile than the S&P 500. Comparatively, PreveCeutical Medical has a beta of 0.43, indicating that its stock price is 57% less volatile than the S&P 500.

Valuation & Earnings

This table compares Harrow and PreveCeutical Medical”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harrow	$199.61 million	5.62	-$17.48 million	($0.56)	-54.56
PreveCeutical Medical	N/A	N/A	-$940,000.00	N/A	N/A

PreveCeutical Medical has lower revenue, but higher earnings than Harrow.

Insider & Institutional Ownership

72.8% of Harrow shares are owned by institutional investors. 13.7% of Harrow shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current recommendations for Harrow and PreveCeutical Medical, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harrow	0	0	6	0	3.00
PreveCeutical Medical	0	0	0	0	0.00

Harrow presently has a consensus target price of $61.40, indicating a potential upside of 100.95%. Given Harrow’s stronger consensus rating and higher probable upside, analysts plainly believe Harrow is more favorable than PreveCeutical Medical.

Profitability

This table compares Harrow and PreveCeutical Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Harrow	-10.19%	-25.01%	-4.27%
PreveCeutical Medical	N/A	N/A	-544.17%

Summary

Harrow beats PreveCeutical Medical on 7 of the 11 factors compared between the two stocks.

About Harrow

Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.

About PreveCeutical Medical

PreveCeutical Medical Inc., a health sciences company, engages in the development of options for preventive and curative therapies utilizing organic and nature identical products. Its pipeline products include Cannabinoid Sol-Gel Delivery, a cannabinoid-based nose-to-brain delivery system that provides relief from various indications, including pain, inflammation, seizures, and neurological disorders; Non-Addictive Analgesic for pain management; BSV Peptide Program that targets cancer progression; and Dual Gene Therapy for type 2 diabetes and obesity. PreveCeutical Medical Inc. is headquartered in West Vancouver, Canada.